Continuous dopaminergic stimulation: state of the art and outlook.
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects; D001058:Apomorphine / Q000008:administration & dosage / Q000627:therapeutic use; D004298:Dopamine / Q000502:physiology*; D004361:Drug Tolerance; D004409:Dyskinesia, Drug-Induced; D006801:Humans; D007260:Infusion Pumps; D008090:Lisuride / Q000008:administration & dosage / Q000009:adverse effects; D001523:Mental Disorders / Q000139:chemically induced; D009068:Movement / Q000187:drug effects; D009462:Neurology / Q000379:methods*; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology; D013268:Stimulation, Chemical
D000978:Antiparkinson Agents; D008090:Lisuride; D001058:Apomorphine; D004298:Dopamine